Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Receivables: 2018-2019

  • Lineage Cell Therapeutics' Non-Current Receivables was N/A to $22.9 million in Q2 2019 from the same period last year, while for Jun 2019 it was $22.9 million, marking a year-over-year change of. This contributed to the annual value of $22.1 million for FY2018, which is N/A change from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Non-Current Receivables of $22.9 million as of Q2 2019, which was up 1.68% from $22.5 million recorded in Q1 2019.
  • Lineage Cell Therapeutics' Non-Current Receivables' 5-year high stood at $22.9 million during Q2 2019, with a 5-year trough of $21.7 million in Q3 2018.
  • In the last 2 years, Lineage Cell Therapeutics' Non-Current Receivables had a median value of $22.3 million in 2018 and averaged $22.3 million.